Nearly 90% Protein Knockdown — and It Still Lost: The Real Deciding Factor Behind Ionis, Alnylam, and ATTR Cardiomyopathy
Nearly 90% Protein Knockdown — and It Still Lost: The Real Deciding Factor Behind Ionis, Alnylam, and ATTR Cardiomyopathy
KRAS Cracked: The 40-Year Battle That Ended with a Standing Ovation at ASCO 2026
KRAS was called "undruggable" for 40 years. At ASCO 2026, daraxonrasib doubled survival in pancreatic cancer — and the room stood up for 42 seconds.
Lilly, J&J, and Jensen Huang's Healthcare Gambit: Two Roads to AI in Medicine
At GTC, pharma giants Eli Lilly and Johnson & Johnson both partnered with NVIDIA on AI—but took very different paths. Here's what their bets reveal about the future of medicine.